Novel target for treating Philadelphia chromosome positive leukemia and application thereof

The invention relates to the field of biological medicine, in particular to a medicine or a diagnostic reagent for treating Philadelphia chromosome positive leukemia by taking synaptic receptor related protein RAPSYN or a gene thereof as a target spot. The invention specifically discloses an applica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DAI BEIYING, CHEN YIJUN, WANG SHUZHEN, ZHAO MENGYA, YANG YONG, LI XIAODONG, ZHANG YIXIN
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to the field of biological medicine, in particular to a medicine or a diagnostic reagent for treating Philadelphia chromosome positive leukemia by taking synaptic receptor related protein RAPSYN or a gene thereof as a target spot. The invention specifically discloses an application of an RAPSYN gene or protein as a therapeutic target in screening and/or preparing a medicine for preventing and/or treating Philadelphia chromosome positive leukemia, and the Philadelphia chromosome positive leukemia can be treated by negatively regulating the level and activity of the RAPSYN gene or protein. The curative effect and prognosis of a patient can be predicted by further detecting the expression level of the RAPSYN. A treatment strategy or medicine taking the RAPSYN gene and protein as targets can be used as a new means for targeted treatment of leukemia. 本发明涉及生物医药学领域，特别是涉及以突触受体相关蛋白RAPSYN或其基因作为靶点制备治疗费城染色体阳性白血病的药物或者诊断试剂。本发明具体公开了以RAPSYN基因或蛋白作为治疗靶点在筛选和/或制备预防和/或治疗费城染色体阳性白血病药物的用途，可通过负向调控RAPSYN基因或蛋白水平和活